Experimental CAR-T therapy shows early promise in Tough-to-Treat myeloma

NCT ID NCT04322292

Completed Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goals were to check safety and see if the treatment could shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C-CAR088 (a type of CAR-T cell therapy targeting BCMA)
What this could lead to: If successful, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 9 participants, so results may not apply broadly. CAR-T therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

InstituteHBDH

Tianjin, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.